semaglutide being pulled from market 🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these In the Weight-Loss Wars, Novo's

The practical point remains: reducing the mental fight around food can be valuable

The clinical proof is thin

SELECT Trial Result: A primary cardiovascular end-point event occurred in 6.5% of semaglutide patients versus 8.0% of placebo patients a hazard ratio of 0.80, representing a statistically significant 20% reduction in major adverse cardiovascular events (MACE)

Serious effects are uncommon and mainly linked to unregulated, high-dose, or non-sterile use

These benefits seem to be related to the user increasing the Glutathione level in the body

No, increased urination is not a recognised side effect of GLP-1 receptor agonists according to MHRA guidance